Objective: To examine whether selective serotonin reuptake inhibitor (SSRI) antidepressants were associated with an increased or decreased risk of cardiovascular adverse events (AEs).
T here is evidence that treatment with SSRIs and other newer antidepressants is associated with greater improvement in depression symptoms in patients with a wide range of physical illnesses-an improvement seen significantly more often than in those treated with either placebo or no treatment (1) . Adverse cardiovascular events associated with SSRIs include arrhythmias, bleeding tendencies, and drug interactions (2) (3) (4) (5) (6) , leading some to suggest that caution should be exercised when prescribing SSRIs to vulnerable patients, including the elderly and those with cardiovascular disease (7) . Conversely, recent studies suggest that SSRIs may have a beneficial effect by reducing cardiovascular events in patients at risk (8) (9) (10) (11) .
Some randomized, placebo-controlled trials treating depression in patients with coronary artery disease or stroke have found that those given SSRIs experienced fewer cardiovascular AEs. The incidence of severe cardiovascular AEs-including death, MI, congestive heart failure, stroke, and angina-in the SADHART trial was 14.5% in the sertraline group and 22.4% in the placebo group, although the difference was not statistically significant (12) . A subgroup analysis of the Enhancing Recovery in Coronary Heart Disease Patients trial (10) found that the risk of death or recurrent MI was significantly lower in the nonrandomized group of patients taking SSRIs, compared with patients who did not receive them, with a hazard ratio of 0.57 (95%CI, 0.38 to 0.84). A randomized, placebo-controlled study of 137 patients without depression who were given sertraline to prevent poststroke depression showed statistically that patients given sertraline over the 12-month period after a stroke experienced fewer severe cardiovascular and noncardiovascular AEs, compared with patients given placebo (11) .
Because there are usually low numbers of serious AEs occurring in small-to medium-sized RCTs, differences in AE rates between groups are usually not significant, and the benefit or risk to patients with respect to these outcomes is not determinable. In light of conflicting evidence concerning the safety of SSRIs in patients at risk for cardiovascular events, we performed a systematic review to examine whether SSRIs are associated with an increased or decreased risk of cardiovascular AEs in the treatment of these patients. We chose trials that involved treating patients with cardiac disease, diabetes mellitus, stroke, and geriatric age, including patients with Alzheimer's disease, nicotine dependence, alcoholism, HIV infection, and obesity (including those with metabolic syndrome).
Methods

Literature Search Strategy
We conducted a systematic literature search to identify all RCTs of SSRIs indexed on MEDLINE between 1967 and May 2005. The search strategy combined the text terms SSRI, serotonin uptake inhibitors, fluoxetine, Prozac, sertraline, Zoloft, paroxetine, Paxil, fluvoxamine, Luvox, citalopram, and Celexa with the Dickersin filter for RCTs (13) . We used the same strategy to search the Cochrane Collaboration's register of randomized and nonrandomized controlled trials (November 2004) for trials produced by the Cochrane Depression, Anxiety, and Neurosis Group. We also reviewed the bibliographies of 3 systematic reviews (14-16) and identified relevant reports. Two authors independently reviewed all citations retrieved from the electronic search to identify potentially relevant trials. When a unanimous decision could not be reached, a third reviewer was consulted to resolve the difference. Citations involving patients at high risk for cardiovascular AEs were selected for analysis from the list of relevant trials.
Identification of Articles and Abstraction of Data
To be eligible for inclusion, studies had to be RCTs comparing an SSRI with either placebo or an active non-SSRI control. Citations were classified by patient population and were considered eligible in studies of stroke, diabetes, the geriatric population (greater than 60 years of age), cardiac disease, HIV infection, smoking cessation, alcoholism, and patients with obesity or metabolic syndrome. We selected these vulnerable populations on the basis of their known associations with cardiovascular disease. We excluded abstracts, crossover trials, and all trials with follow-ups of less than 1 week. Crossover trials were excluded because of both the difficulty in appropriately attributing an outcome to treatment as well as the poor reporting of the relation between AEs and treatment. We developed a standardized data abstraction form that included patient population, modes of treatment compared, patients' demographics, and the number of patients randomly assigned to each treatment group. Because our primary aim was to evaluate relatively rare, potentially serious AEs, and not treatment effectiveness, we did not use a formal quality scale to quantify the quality of individual study reports. We limited eligibility to trials that were truly randomized and examined individual sources of clinical and methodological heterogeneity, including clinical indication, trial duration, sex, age, sample size, and dropouts.
Outcomes
We considered any reported cardiovascular AE to be a relevant outcome for the review. Serious cardiovascular AEs were defined as death owing to a cardiovascular cause, heart failure, TIA, stroke, and MI. Nonserious cardiovascular AEs were defined as palpitations, chest pain, angina, arrhythmia (tachycardia, bradycardia, irregular heart beat, and abnormal electrocardiogram QRS findings), hypertension, or hypotension-syncope, as well as unspecified cardiovascular or neurological events. Two authors independently reviewed all trials and classified cardiac outcomes; if a unanimous decision could not be reached, the third author was consulted to resolve the difference.
Methodological Considerations
We documented how AEs were reported, dropout rates, sample size, and the number of trials that did not report AEs. To deal with poor reporting of AEs, we included a "not reported" category. This category comprised trials that did not mention AEs or reasons for discontinuation of therapy, provided an incomplete listing of all AEs, or did not explicitly state that no AEs had been observed. We also documented the proportion of trials that reported AEs beyond percentage thresholds (for example, 5%) as well as trials with AEs occurring in more than a defined number of patients.
Analysis
As an initial description of cardiovascular AEs in different patient populations, we calculated the overall rates of both serious and nonserious cardiovascular AEs across the predefined population subgroups. To evaluate the association between cardiovascular AEs and the use of SSRIs, we calculated aggregate rates of specific AE types in 3 separate treatment groups. Comparisons included SSRIs, TCAs, and other active forms of therapy excluding placebo and TCAs. We tested the association between cardiovascular AEs and the use of SSRIs by calculating ORs according to fix-effects models for all studies independent of the patient population or treatment indications. ORs and 95%CIs were calculated with the Peto method (17) (18) (19) . The analyses included trials that reported the number of cardiovascular AEs. Trials categorized as "not reported" were not incorporated into the analyses. Given that AEs were extremely uncommon, which resulted in difficulties with empty cells, we did not conduct any tests for heterogeneity.
Results
The literature search identified a total of 3717 citations. After an initial review by at least 2 authors, 1135 trials were deemed potentially eligible. Of these, we excluded 373 trials for the following reasons: duplicate publication (n = 125), not an RCT (n = 118), SSRI control only (n = 62), no SSRI arm (n = 13), subgroup analysis (n = 20), foreign language other than French or English (n = 13), short trial duration (n = 12), and incomplete or inaccessible data (n = 10). We identified an additional 78 trials meeting eligibility criteria by electronically searching the Cochrane Collaboration register of controlled trials (Cochrane Depression, Anxiety, and Neurosis Group) and by a manual review of the bibliographies of 3 published systematic reviews (28) (29) (30) . Of the 840 eligible trials, 122 were conducted in our predefined patient groups at high risk for cardiovascular AEs.
The 122 trials comprised 85 comparisons between SSRIs and placebo, 26 comparisons between SSRIs and TCAs, and 20 comparisons between SSRIs and active therapies other than placebos or TCAs (nontricyclic antidepressants, n = 12; psychotherapy, n = 3; benzphetamine, n = 1; perphenazine, n = 1; piracetam, n = 1; fenfluramine, n = 1; indomethacine, n = 1). As some trials had more than one comparison arm, the total number of comparisons exceeds the number of published trials. There were an insufficient number of longer-term trials (n = 9) to conduct sensitivity analysis of short-term, compared with long-term, trial duration on cardiac outcomes. In a sensitivity analysis removing the longer-term trials ( > 14 weeks), overall results did not significantly change. Of the 9 trials, only 3 had potential duration greater than 26 weeks (range 16 to 52 weeks). Table 1 describes the trial characteristics according to the 8 high-risk patient populations in the analyzed trials, and it also includes the number of trials per group that reported cardiovascular AEs. The majority (53%) of the total 13 828 patients were treated in trials of the geriatric age group (age greater than 60). The mean age of patients was 58 years, and 58% of participants were women. Both sex and age were uniformly distributed across patient populations, with the exception of a higher proportion of women in the obesity trials, a lower proportion in subjects with alcoholism, and older patients in the geriatric group.
A total of 50 trials that reported cardiovascular AEs were included in the analysis; these trials reported 6588 patients with cardiovascular AEs (379 in total). Of the 50 trials reporting cardiovascular AEs, 39 reported at least one event, while the other 11 explicitly reported no events. In comparing patient characteristics between trials that reported cardiovascular AEs and those that did not, the only significant difference we found was in the stroke patient trial group, where all 11 trials explicitly reported cardiovascular AEs (P < 0.01). Of the 122 trials, 26 (21%) did not report AEs beyond prespecified thresholds (that is, 5% or 10% of a treatment or control group). decreased risk of serious cardiovascular AEs in patients treated with SSRIs, compared with placebo, there was insufficient power to detect a statistically significant association. Factors leading to the lack of power include the rarity of serious cardiovascular events, a lack of reporting, and the lack of published trials. In addition, we found that patients given SSRIs appear to have a lesser risk of nonserious cardiovascular AEs, compared with those given TCAs. This is consistent with the well-recognized cardiovascular side effects of TCAs, which make their use undesirable in patients with ischemic cardiac disease and other medical conditions (20) .
Observational studies of the relation between SSRI use and cardiovascular events have shown conflicting results. Concordant with our results, a case-control study involving 653 patients with MI and 2990 control subjects reported that the OR for MI among current SSRI users, compared with nonusers, was 0.35 (95%CI, 0.18 to 0.68) (8) . In contrast, a case-control study of over 60 000 patients with MI and 360 000 control subjects found that there was an initial increased risk of MI in the first 28 days after exposure to TCAs or SSRIs, with similar size effects; however, the authors speculate that the similar risk between drug classes may reflect the influence of depression itself and, consequently, is not related to the antidepressant medication (21) .
Depression patients with and without coronary artery disease have been shown to have increased platelet reactivity that may make them predisposed to thrombus formation, MI, and stroke (22, 23) . A substudy of the SADHART trial found that treatment with an SSRI in depression patients with unstable angina or acute MI was associated with reduction in platelet-endothelial activation despite coadministration of antiplatelet regimens (9) , suggesting that there may be a benefit of SSRI administration to depression patients with coronary artery disease. Notwithstanding possible benefits of SSRIs on cardiovascular outcomes, some case reports and observational studies suggest SSRIs may be related to AEs such as bradyarrhythmias and bleeding disorders (2) (3) (4) (5) . Further, some SSRIs interact with common cardiac and noncardiac medications, which should be of concern to patients with complex medical disorders because these interactions could increase the risk of adverse outcomes (6) . Given these concerns, our findings are reassuring; however, the limitations of this study must also be considered.
Limitations and Conclusions
An important limitation of this study is that over one-half of the trials did not report cardiovascular events. In 66 trials involving a total of 6653 patients, which accounted for slightly more than one-half of all trials reviewed, there was no information on cardiovascular AEs. With respect to the high-risk group among most patients, the geriatric group comprised 52 trials involving 7334 patients, but 26 of these trials (involving 3807 patients) did not report any cardiovascular AEs. Further, reporting of events that involve more than 5% or 10% of patients in either the active drug or placebo groups is often standard practice for clinical trials of antidepressants, yet not reporting absolute numbers of events in either category of patients obscures important drug-placebo differences that might be uncovered by systematic reviews such as this study.
Determining the most effective approach to AE ascertainment in a clinical trial is controversial, with some advocating general inquiry with open-ended questions and relying on spontaneous reporting of events and others advocating specific inquiry with recording of symptoms elicited by checklists of common symptoms (24) (25) . Another issue involves the subjective nature of determining whether an AE is related to the quality or nature of the underlying illness or to the quality or nature of the treatment given. This is a problem in the investigation of hospitalization-related AEs (26) , and we also found this to be true of many clinical trials reviewed in this study. We agree with Vida and Looper (27) , who reviewed the precision and comparability of AE rates of newer antidepressants and recommended that all serious AEs should be reported, even if rates are low, and that AEs should be reported regardless of whether or not they are attributed to the study drug.
Several investigators have called for a large RCT to determine whether SSRIs can reduce cardiac events in patients with coronary disease (28) (29) (30) . We suggest that rigorous assessment and reporting of cardiovascular AEs must be given particular consideration in designing such a trial and that improved reporting of AEs occur in all future trials of antidepressant medications.
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